• Impressum
• Suche
• Kontakt
• Anreise
• Sitemap

09/1984 - 03/1991	Study of Biology at Friedrich-Wilhelms-University Bonn
03/1991	Diploma („magna cum laude“)
01/1992 - 08/1994	PhD Studies at Friedrich-Wilhelms-University Bonn
08/1994	Dissertation („summa cum laude“)
10/1994 - 11/1997	DMSc Studies at University of Cologne
11/1997	Dissertation („magna cum laude“)
06/2001	Habilitation, Experimental Internal Medicine at University of Cologne

06/2006 - present	Full Professor, Head, Experimental Medicine and Immunotherapy at AME, Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University
11/2003 - present	Co-Founder, PharmedArtis GmbH, Aachen
9/2000 - present	Head, Division of Molecular Biology, Head, Dept. of Pharmaceutical Product Development at Fraunhofer-Institute for Molecular Biology and Applied Ecology, Aachen
10/1994 - 08/2000	Senior scientist, Laboratory of Immunotherapy, Dept. of Internal Medicine I, University of Cologne
10/1992 - 09/1994	Research Associate, PhD student, Institute of Agricultural Botany at the Friedrich-Wilhelms-University of Bonn
04/1992 - 10/1992	Project Coordinator, Institute of Theoretic Physiscs at the Friedrich-Wilhelms-University of Bonn

• Project leader, gentechnological S2-Facility (64-K-1.50/05) at Fraunhofer IME
• International Association for Plant Tissue Culture, Member
• German Society for Hematology and Oncology, Member
• German Cancer Society, Member
• European Association for Cancer Research, Member
• German-Israelian Life Science Committee, Member
• German Research Foundation and Alexander-von-Humboldt Foundation, Reviewer
• Reviewer for peer-reviewed journals: “Protein Engineering, Design, and Selection”, “Life Sciences”, “Current Medicinal Chemistry Anti-Inflammatory and Anti-Allergy Agents”, “Recent Patents on Anti-Cancer Drug Discovery“, “Recent Patents on Nanotechnology”, “Biotechnology and Applied Biochemistry”, “Cancer Letters”, “The Open Cancer Journal”, “Biological Chemistry”, “Immunology Letters”, “Bioconjugate Chemistry”, “Molecular Cancer Therapeutics”

• 1st Poster prize, Ribbert M., Barth S., Finnern R. – Generation of antibodies against Venturia inaequalis ascospores for use in an antibody-based pathosensor. Bioforum Aachen: A46 (2003)
• 1st Poster prize, Klockenbring T., Stöcker M., Huhn M., Petersen A., Bauer R., Goerlich R., Fischer R., Barth S. – Antigen-specific targeting and elimination of EBV-transformed B cells by allergen-toxins. Allergo J 13 Suppl. 1: S62 (2004)
• 1st Prize, PharmedArtis, start2grow Gründungswettbewerb für alle Branchen 2005, Phase 2 (Dortmund) (2006)
• Funding Prize, PharmedArtis, NUK-Businessplan-Wettbewerb (2006)
• 1st Prize, PharmedArtis, Gründungswettbewerb AC2 – gründen und wachsen (Aachen) (2006)
• 1st Poster prize, Neef I., Wüllner U., Eller A., Kleines M., Tur M.K., Barth S. – Antigen-specific delivery of siRNA against eukaryotic elongation factor 2 by rationally-designed bivalent aptamer-siRNA transcripts. The RNAi World Congress, April 24-25, Philadelphia, USA (2007)
• Lesmüller-Poster prize, Fitting J., Barth S., Tur M.K. – Selection of internalizing scFv-antibodies from naïve phage display libraries for targeted leukemia therapy. DPHG-Jahrestagung, Oktober 8-11, Bonn (2008)

Prof. Barth started his work in Aachen at the end of 2000 and meanwhile manages research groups of >30 members exclusively funded by grants and composed of both Fraunhofer and university employees. During the last 15 years of work in the field of biotechnology he successfully applied for 35 funded projects, thus raised ~ 14.420.000 EURO, filed 18 different patents applications, and wrote more than 80 scientific articles.

1. Barth S. – Recombinant immunotoxins – The next generation. Current Pharmaceutical Design 15 (23): 2650-2651 (2009) IF 4.399
2. Barth S., Huhn M., Matthey B., Klimka A., Galinski E.A., Engert A. - Compatible solute-supported periplasmic expression of functional recombinant proteins under stress conditions. Appl. Environm. Microbiol. 66(4): 1572-1579 (2000) IF 3.532
3. Barth S., Huhn M., Matthey B., Tawadros S., Schnell R., Diehl V., Engert A. - Ki-4(scFv)-ETA’, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 95 (12): 3909-3914 (2000) IF 10.370
4. Hetzel C., Bachran C., Fischer R., Fuchs H., Barth S.*, Stöcker M.* – Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin against CD64-positive acute myeloid leukemia cells. J. Immunother. 31(4): 370-376 (2008) IF 4.399
5. Huhn M., Sasse S., Tur M.K., Matthey B., Schinköthe T., Rybak S., Barth S., Engert A. - Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res. 61(24): 8737-8742 (2001) IF 7.656
6. Joerissen H., Bektas N., Dahl E., Hartmann A., ten Haaf A., Di Fiore S., Kiefer H., Thess A., Barth S.*, Klockenbring T.* - Production and characterization of monoclonal antibodies against RAI3 andits expression in human breast cancer. BMC Cancer 9: 200 (2009) IF 3.08
7. Kampmeier F., Ribbert M., Nachreiner T., Demsky S., Beaufils F., Brecht A., Barth S. – Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-methylguanine DNA alkyltransferase. Bioconjug. Chem.: in press (2009) IF 4.584
8. Nachreiner T., Kampmeier F., Thepen T., Fischer R., Barth S.*, Stöcker M.* – Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin. J. Neuroimmunology 195(1-2): 28-35 (2008) IF 2.88
9. Pfitzner T., Engert A., Wittor H., Schinköthe T., Winkler U., Schulz H., Diehl V., Barth S. - A real-time PCR assay for the quantification of residual malignant cells in monoclonal B-cell lymphomas. Leukemia 14: 754-766 (2000) IF 6.146
10. Ranft K., Thepen T., Fischer R., Barth S.*, Stöcker M.* - Recombinant bispecific single chain antibody fragments induce Fc-gamma receptor mediated elimination of CD30+ lymphoma cells. Cancer Lett. 282(2): 187-94 (2009) IF 3.504
11. Ribbert T., Thepen T., Tur M.K., Fischer R., Huhn M., Barth S. – Recombinant, ETA’-based CD64 immunotoxins: Improved efficacy by increased valency, both in vitro as well as in vivo in a chronic cutaneous inflammation model in hC64-transgenic mice. British Journal of Dermatology: accepted (2009) IF 3.489
12. Rosenblum M.G., Barth S. – Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions. Current Pharmaceutical Design 15 (23): 2676-2692 (2009) IF 4.399
13. Stahnke B., Thepen T., Stöcker M., Rosinke R., Jost E., Fischer R., Tur M.K., Barth S. – Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukaemia of monocyte subtypes. Molec. Cancer Therap. 7(9): 2924-2932 (2008) IF 5.003
14. Stöcker M., Klockenbring T., Huhn M., Nachreiner T., Wicklein D., Petersen A., Bauer R., Goerlich R., Fischer R., Barth S. – Antigen-specific targeting and elimination of EBV-transformed B-cells by allergen-toxins. Journal of Allergy and Clinical Immunology 116(4): 910-915 (2005) IF 8.829
15. Thepen T., Huhn M., Melmer G., Tur M.K., Barth S. – Fcg receptor 1 (CD64), a target beyond cancer therapy. Current Pharmaceutical Design 15 (23): 2712-2718 (2009) IF 4.399
16. Thumann G., Stöcker M., Maltusch C., Salz A., Barth S., Walter P., Johnen S. – High efficient non-viral transfection of retinal and iris pigment epithelial cells with pigment epithelial-derived factor (PEDF). Gene Therapy: accepted (2009) IF 4.492
17. Tur M.K., Huhn M., Thepen T., Stöcker M., Krohn R., Vogel S., Jost E., Osieka R., van de Winkel J.G., Fischer R., Finnern R., Barth S. - Recombinant CD64-specific single chain Immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res. 63 (23): 8414-8419 (2003); 64: 3725 (2004) IF 7.656
18. Tur M.K., Neef I., Jäger G., Teubner A., Stöcker M., Melmer G., Barth S. – Immunokinases, a novel class of immunotherapeutics for targeted cancer therapy. Current Pharmaceutical Design: Current Pharmaceutical Design 15 (23): 2693-2699 (2009) IF 4.399
19. Tur M.K., Neef I., Jost E., Galm E., Jäger G., Stöcker M., Ribbert M., Osieka R., Barth S. – Targeted restoration of downregulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells. J. Immunother. 32 (5): 431-441 (2009) IF 3.662
20. Wüllner U., Neef I., Eller A., Kleines M., Tur M.K., Barth S. – Disease-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr. Cancer Drug Targets 8(7): 554-565 (2008) IF 4.316